Remove 2021 Remove Bipolar disorder Remove Eating disorders
article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

News Media Peer Exchange Case-Based Psych Perspectives Clinical Case Collective Insights Peers & Perspectives Slideshows Videos Conferences Conference Coverage Conference Listing Publication Psychiatric Times Job Board CME/CE Partners Editorial Resources Between the Lines Expert Perspectives Clinical Consult Clinical Scales Interactive Tools Partner (..)

article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

Related Videos Related Content Advertisement June 17th 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Jonathan E. Jonathan E.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

Psychiatric Times

Related Videos Related Content Advertisement July 7th 2025 The Psychiatric Pipeline in Review: Quarter 2, 2025 Leah Kuntz September 27th 2021 Treating ‘Morally Objectionable’ Patients James L.

article thumbnail

The 2025 Summer Heatwave: Implications for Patients With Psychiatric Disorders

Psychiatric Times

Goldberg, MD, and Anita H. Clayton, MD Heidi Anne Duerr, MPH May 20th 2025 Study Finds Zuranolone Effective for Anhedonia in Patients With PPD Heidi Anne Duerr, MPH Related Content Advertisement June 13th 2025 Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score John J. Goldberg, MD, and Anita H.

article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

News Media Around the Practice Between the Lines PsychView Expert Perspectives Case-Based Psych Perspectives Clinical Case Collective Dialogues Payer-Provider Perspective Slideshows Videos Viewpoints Conferences Conference Coverage Conference Listing Publication Psychiatric Times Job Board CME/CE Partners Editorial Resources Clinical Consult Clinical (..)

article thumbnail

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

Psychiatric Times

She has been on an antipsychotic medication to treat her bipolar disorder for 10 years, resulting in stability of mood symptoms that were previously poorly controlled. How can this be? Let’s review a few case examples. Case 1 “Ms Robbins” is 49 years old and works as a bank teller.

article thumbnail

TSND-201 Receives Breakthrough Therapy Designation From FDA for PTSD

Psychiatric Times

Related Videos Related Content Advertisement July 8th 2025 sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia Leah Kuntz April 6th 2021 David Hellerstein, MD: Psychedelic Treatments for Psychiatric Disorders Angela A.